Beijing: Biocytogen Pharmaceuticals (Beijing) Co., Ltd. announced the United States Patent and Trademark Office (USPTO) patent grant for independently developed Rainlight® Fully human common light chain mouse platform.

Rainlight Developed using Biocytogen’s proprietary size-unlimited and precise chromosome engineering (SUPCETM) technology, the mice contain in-situ replacement of the entire human antibody heavy chain variable region gene and a single light chain variable region gene.

This makes it possible to create a highly diverse, fully human generation. Antibody which share a common light chain, thereby effectively avoiding light-heavy chain mismatches during the assembly of bispecific antibodies, significantly reducing the complexity of the CMC process. The molecular structure of these bispecific antibodies resembles that of monoclonal antibodies, exhibiting favorable physicochemical properties.

Leveraging RenLight and RenLight KO mice, Biocytogen has generated a library of antibodies targeting more than 200 TAA targets, enabling the rapid development of bispecific antibodies and bispecific antibody-drug-conjugate (ADC) therapies. In addition to the RenLight platform, Biocytogen has independently developed Rainmice® series includes the RenMabTM, RenNano®, RenTCRTM and RenTCR-mimicTM platforms.

These five fully human antibody/TCR mouse platforms meet the diverse R&D needs of pharmaceutical companies globally. Since their launch in 2019, Rainmice The platform has gained widespread recognition in the biotech and pharmaceutical industries. As of December 31, 2023, Biocytogen has established 47 target-nominated Renomyces licensing projects with more than 20 multinational corporations (MNCs) and biopharmaceutical/biotech companies, including Merck KGaA, Janssen, Xencor, BeiGene, and Innovent.

The RenMice platform has generated a library of more than 400,000 fully human antibodies against thousands of targets and high-quality candidate antibodies, facilitating 103 projects involving co-development, out-licensing and transfer agreements. The US patent authorization for the RenLight platform technology reflects Biocytogen’s exceptional innovation capabilities and global competitiveness. Biocytogen will continue to pursue global patent strategies and protect key technologies, providing advanced technology platforms and strong intellectual property protection for its partners. In addition to the United States, patent applications for the RenLight platform have been submitted in China, Europe, Japan, South Korea, Canada, Singapore, Russia, Israel, Australia and other countries and regions, with authorizations in progress. PTI PWR PWR